tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Compass Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsCompass Therapeutics Reports Q3 2025 Financial Results
28d ago
Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
Premium
Ratings
Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
29d ago
Compass Therapeutics reports Q3 EPS (8c), consensus (13c)
Premium
The Fly
Compass Therapeutics reports Q3 EPS (8c), consensus (13c)
29d ago
Buy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment
PremiumRatingsBuy Rating for Compass Therapeutics Driven by Promising Clinical Trial Data and Strategic Enrollment
2M ago
Compass Therapeutics initiated with an Outperform at LifeSci Capital
Premium
The Fly
Compass Therapeutics initiated with an Outperform at LifeSci Capital
2M ago
Positive Outlook for Compass Therapeutics: Buy Rating Backed by Promising Pipeline and Market Potential
Premium
Ratings
Positive Outlook for Compass Therapeutics: Buy Rating Backed by Promising Pipeline and Market Potential
2M ago
Compass Therapeutics price target raised to $12 from $10 at Guggenheim
PremiumThe FlyCompass Therapeutics price target raised to $12 from $10 at Guggenheim
4M ago
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
Premium
Company Announcements
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions
4M ago
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress
Premium
Company Announcements
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100